Stable and high-yielding intrinsic (59) Fe-radiolabeling of the intravenous iron preparations Monofer and Cosmofer.
Commercial iron supplements Monofer(®) and Cosmofer(®) were intrinsically radiolabeled with (59) Fe for the purpose of tracing iron absorption in vivo. Optimized procedures aimed at introducing (59) Fe into the macromolecular construct in a form that was as chemically equivalent to the matrix iron as possible. This was determined by challenging the labeled constructs with diethylenetriaminepentaacetic acid (DTPA) followed by separation by size-exclusion and measurements of radioactivity and iron in the eluted fractions. The final procedures were simple and involved heating aqueous dispersions of the supplements in the presence of [(59) Fe]FeCl3 for 24 h at 95 °C for Monofer, and 85 °C for Cosmofer, resulting in radiochemical yields greater than 94%. High performance size exclusion chromatography, UV-VIS spectroscopy, and dynamic light scattering were used to show that the supplements remained unchanged after radiolabeling, underscoring the applicability of the methodology for radiolabeling commercial iron preparations.
Technical University of Denmark, The Hevesy Laboratory - Center for Nuclear Technologies (DTU Nutech), Roskilde, Denmark.
Andreas I
0000-0002-9085-8603
AI
Jensen
Technical University of Denmark, The Hevesy Laboratory - Center for Nuclear Technologies (DTU Nutech), Roskilde, Denmark.
Gregory W
GW
Severin
Pharmacosmos A/S, Holbaek, Denmark.
Hans B
HB
Andreasen
Technical University of Denmark, The Hevesy Laboratory - Center for Nuclear Technologies (DTU Nutech), Roskilde, Denmark.
Palle H
PH
Rasmussen
D061605:Administration, Intravenous; D019587:Dietary Supplements; D007501:Iron / Q000008:administration & dosage* / Q000737:chemistry* / Q000378:metabolism; D007504:Iron Radioisotopes / Q000737:chemistry*; D007553:Isotope Labeling; D011854:Radiochemistry
D007504:Iron Radioisotopes; D007501:Iron
Fe-59; cosmofer; intravenous iron therapy; intrinsic radiolabeling; iron supplements; monofer